PT - JOURNAL ARTICLE AU - ANCA MARIA CIMPEAN AU - IONUT MARCEL COBEC AU - RALUCA AMALIA CEAUȘU AU - ROXANA POPESCU AU - ANCA TUDOR AU - MARIUS RAICA TI - Platelet Derived Growth Factor BB: A “<em>Must-have</em>” Therapeutic Target “<em>Redivivus</em>” in Ovarian Cancer DP - 2016 Nov 01 TA - Cancer Genomics - Proteomics PG - 511--517 VI - 13 IP - 6 4099 - http://cgp.iiarjournals.org/content/13/6/511.short 4100 - http://cgp.iiarjournals.org/content/13/6/511.full SO - Cancer Genomics Proteomics2016 Nov 01; 13 AB - Background: We aimed to validate PDGF-BB protein expression by RNAscope, a sensitive method for PDGF-BB mRNA evaluation on paraffin embedded (FFPE) specimens of ovarian tumors. Materials and Methods: Seventy-five FFPE ovarian cancer biopsies were assessed by immunohistochemistry followed by PDGF-BB mRNA RNAscope validation. Results and Conclusion: Dual PDGF-BB expression in tumor and stromal cells have been observed, being highly suggestive for PDGF-BB mediated stromal-tumor cells reciprocal interaction in ovarian cancer (p=0.008). It seems that the nuclear expression of the PDGF-BB represents a negative prognostic factor in ovarian tumors. Being a controversial issue in the literature, PDGF-BB nuclear expression detected by immunohistochemistry was validated by RNAscope in situ hybridization. More than 65% of cases had PDGF-BB mRNA amplification, confirming immunohistochemical results. We herein validated PDGF-BB as a potential therapeutic and prognostic tool of ovarian cancer aggressiveness.